Findings

What do systematic reviews say?

508 questions · 529 findings · 58 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 191 · 36.1%GRADE not reported 49 · 9.3%Very low 143 · 27%Low 92 · 17.4%Moderate 51 · 9.6%High 3 · 0.6%

Injectional verapamil vs saline (short‐term)

Degree of penile curvature · men with Peyronie's disease (palpable plaque or pain)

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Very low

Injectional verapamil vs saline (short‐term)

Treatment discontinuation · men with Peyronie's disease (palpable plaque or pain)

The review found no eligible studies for this question.

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Injectional interferon alpha‐2B vs Normal saline

Outcomes ( · men with chronic (≥ 12 months) Peyronie's disease (single plaque)

The review found no eligible studies for this question.

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Injectional interferon alpha‐2B vs Normal saline

Patient‐reported ability to have intercourse · men with chronic (≥ 12 months) Peyronie's disease (single plaque)

The review found no eligible studies for this question.

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Injectional interferon alpha‐2B vs Normal saline

Quality of life · men with chronic (≥ 12 months) Peyronie's disease (single plaque)

The review found no eligible studies for this question.

1 finding from 1 review

Non‐surgical therapies for Peyronie's disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tranexamic acid vs placebo (saline solution or sterile water)

Surgical field bleeding score (during surgery or < 30 minutes after surgery) · adults and children with chronic rhinosinusitis with or without nasal polyps

1 finding from 1 review

Tranexamic acid for the reduction of bleeding during functional endoscopic sinus surgery 2023 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 772 participants
Moderate

Tranexamic acid vs placebo (saline solution or sterile water)

Intraoperative blood loss (mL) · adults and children with chronic rhinosinusitis with or without nasal polyps

1 finding from 1 review

Tranexamic acid for the reduction of bleeding during functional endoscopic sinus surgery 2023 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 802 participants
Low

Tranexamic acid vs placebo (saline solution or sterile water)

Significant adverse events (seizures, thromboembolism) within 24 hours of surgery) · adults and children with chronic rhinosinusitis with or without nasal polyps

Tranexamic acid showed no clear difference in significant adverse events (seizures, thromboembolism) within 24… compared with placebo (saline solution or sterile water) (moderate certainty).

1 finding from 1 review

Tranexamic acid for the reduction of bleeding during functional endoscopic sinus surgery 2023 · Cochrane Headline outcomes only
RD 0
8 studies · 664 participants
Moderate

Tranexamic acid vs placebo (saline solution or sterile water)

Duration of surgery (minutes) Assessed as: total surgical time · adults and children with chronic rhinosinusitis with or without nasal polyps

1 finding from 1 review

Tranexamic acid for the reduction of bleeding during functional endoscopic sinus surgery 2023 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 666 participants
Moderate

Tranexamic acid vs placebo (saline solution or sterile water)

Incomplete surgery · adults and children with chronic rhinosinusitis with or without nasal polyps

Tranexamic acid showed no clear difference in incomplete surgery compared with placebo (saline solution or sterile water) (moderate certainty).

1 finding from 1 review

Tranexamic acid for the reduction of bleeding during functional endoscopic sinus surgery 2023 · Cochrane Headline outcomes only
RD 0
2 studies · 58 participants
Moderate

Tranexamic acid vs placebo (saline solution or sterile water)

Overall rate of surgical complications · adults and children with chronic rhinosinusitis with or without nasal polyps

Tranexamic acid showed no clear difference in surgical complications compared with placebo (saline solution or sterile water) (moderate certainty).

1 finding from 1 review

Tranexamic acid for the reduction of bleeding during functional endoscopic sinus surgery 2023 · Cochrane Headline outcomes only
RD 0
2 studies · 58 participants
Moderate

Tranexamic acid vs placebo (saline solution or sterile water)

Postoperative bleeding (place of packing or revision surgery within 14 days of surgery) · adults and children with chronic rhinosinusitis with or without nasal polyps

Tranexamic acid showed no clear difference in postoperative bleeding (place of packing or revision surgery within… compared with placebo (saline solution or sterile water) (low certainty).

1 finding from 1 review

Tranexamic acid for the reduction of bleeding during functional endoscopic sinus surgery 2023 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 404 participants
Low

Local corticosteroid injection (LCI) vs saline no treatment or placebo

Improvement in symptoms at ≤ 3 months · carpal tunnel syndrome

1 finding from 1 review

Local corticosteroid injection versus placebo for carpal tunnel syndrome 2023 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 579 participants
Moderate

Local corticosteroid injection (LCI) vs saline no treatment or placebo

Improvement in function at ≤ 3 months · carpal tunnel syndrome

1 finding from 1 review

Local corticosteroid injection versus placebo for carpal tunnel syndrome 2023 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 499 participants
Moderate

Local corticosteroid injection (LCI) vs saline no treatment or placebo

Improvement in symptoms at > 3 months · carpal tunnel syndrome

1 finding from 1 review

Local corticosteroid injection versus placebo for carpal tunnel syndrome 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 234 participants
Moderate

Local corticosteroid injection (LCI) vs saline no treatment or placebo

Improvement in neurophysiological parameters at ≤ 3 months · carpal tunnel syndrome

1 finding from 1 review

Local corticosteroid injection versus placebo for carpal tunnel syndrome 2023 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 359 participants
Very low

Local corticosteroid injection (LCI) vs saline no treatment or placebo

Requirement for carpal tunnel surgery · carpal tunnel syndrome

Local corticosteroid injection (LCI) probably leads to lower requirement for carpal tunnel surgery compared with saline no treatment or placebo (moderate certainty).

1 finding from 1 review

Local corticosteroid injection versus placebo for carpal tunnel syndrome 2023 · Cochrane Headline outcomes only
RR 0.84 [0.72, 0.98]
1 study · 111 participants
Moderate

Local corticosteroid injection (LCI) vs saline no treatment or placebo

Improvement in quality of life · carpal tunnel syndrome

1 finding from 1 review

Local corticosteroid injection versus placebo for carpal tunnel syndrome 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 111 participants
Moderate

Local corticosteroid injection (LCI) vs saline no treatment or placebo

Adverse events · carpal tunnel syndrome

1 finding from 1 review

Local corticosteroid injection versus placebo for carpal tunnel syndrome 2023 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 639 participants
Low

Hyperimmune immunoglobulin from human plasma vs saline placebo

All‐cause mortality at day 28 · individuals with moderate or severe COVID‐19

Hyperimmune immunoglobulin from human plasma showed no clear difference in all‐cause mortality at day 28 compared with saline placebo (low certainty).

1 finding from 1 review

Hyperimmune immunoglobulin for people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.79 [0.43, 1.44]
Studies not reported
Low